Characterization of Human T Cells Against Chlamydia

人类 T 细胞抗衣原体的特性

基本信息

  • 批准号:
    7225225
  • 负责人:
  • 金额:
    $ 34.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-05-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chlamydia trachomatis (Ct) is the most common cause of bacterial sexually transmitted disease worldwide. In the majority of infected individuals they are asymptomatic. This poses a heath risk for women, causing pelvic inflammation and tubal infertility, and for newborns from infected mothers. Our goal is to characterize the human T cell immune response to Ct in infected individuals with the goal of identifying immunogenic proteins and peptides that could be used for vaccine development. We will determine whether CD4 or CD8 T cell responses can be elicited against Ct proteins that enter the MHC class I or class II antigen processing pathway or are likely to enter those pathways. Specific peptide epitopes from these proteins and the HLA allotypes that present the peptides will be determined using a unique panel of B lymphoblastoid lines expressing single HLA antigens. Our hypothesis is that some regions of immunogenic proteins will contain epitope clusters for both CD4 and CD8 T cells as we found for the major outer membrane protein MOMP. The functional characteristics of the Ct-specific T cells will be determined using antibodies against cytokines, proteins involved in cytotoxicity, and cell surface molecules. Assays such as the Lysispot assay will be used to determine CTL function. Ct-specific T cells in the blood of infected individuals will be enumerated with MHC class I tetramer and class II tetramers. We will determine if the CD8 T cells recognizing Ct antigens are functional CTL cells or potentially "exhausted" T cells lacking CTL activity, which has been found in chronic viral infections. The potential for immunogenic epitopes to cross-protect other Ct species such as C. pneumonia and C. psittaci will be determined by sequence comparisons. Characterizing human T cell responses to Ct is important for understanding immunity to Ct in humans and for future vaccine development.
描述(由申请人提供):沙眼衣原体(Ct)是世界上最常见的细菌性传播疾病。在大多数感染者中,他们是无症状的。这对妇女造成健康风险,引起盆腔炎和输卵管不孕,对受感染母亲所生的新生儿也是如此。我们的目标是表征感染个体对Ct的人类T细胞免疫反应,目的是鉴定可用于疫苗开发的免疫原性蛋白和肽。我们将确定CD4或CD8 T细胞反应是否可以针对进入MHC I类或II类抗原加工途径或可能进入这些途径的Ct蛋白引起。这些蛋白的特异性肽表位和呈递肽的HLA同种异体将使用表达单一HLA抗原的B淋巴母细胞样细胞系的独特小组来确定。我们的假设是免疫原性蛋白的某些区域将包含CD4和CD8 T细胞的表位簇,正如我们在主要的外膜蛋白MOMP中发现的那样。ct特异性T细胞的功能特征将通过对抗细胞因子、参与细胞毒性的蛋白质和细胞表面分子的抗体来确定。Lysispot等检测将用于确定CTL功能。感染个体血液中的ct特异性T细胞将被列举为MHC I类四聚体和II类四聚体。我们将确定识别Ct抗原的CD8 T细胞是功能性CTL细胞还是在慢性病毒感染中发现的缺乏CTL活性的潜在“耗尽”T细胞。免疫原性表位交叉保护其他Ct物种(如肺炎C.和鹦鹉螺C.)的潜力将通过序列比较来确定。表征人类T细胞对Ct的反应对于了解人类对Ct的免疫和未来的疫苗开发非常重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paula B. Kavathas其他文献

Paula B. Kavathas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paula B. Kavathas', 18)}}的其他基金

Characterization of Human T Cells Against Chlamydia
人类 T 细胞抗衣原体的特性
  • 批准号:
    6891090
  • 财政年份:
    2004
  • 资助金额:
    $ 34.88万
  • 项目类别:
Characterization of Human T Cells Against Chlamydia
人类 T 细胞抗衣原体的特性
  • 批准号:
    6738934
  • 财政年份:
    2004
  • 资助金额:
    $ 34.88万
  • 项目类别:
Characterization of Human T Cells Against Chlamydia
人类 T 细胞抗衣原体的特性
  • 批准号:
    7052078
  • 财政年份:
    2004
  • 资助金额:
    $ 34.88万
  • 项目类别:
Characterization of Human T Cells Against Chlamydia
人类 T 细胞抗衣原体的特性
  • 批准号:
    7414396
  • 财政年份:
    2004
  • 资助金额:
    $ 34.88万
  • 项目类别:
Characterization of Human T Cells Against Chlamydia
人类 T 细胞抗衣原体的特性
  • 批准号:
    6332135
  • 财政年份:
    2001
  • 资助金额:
    $ 34.88万
  • 项目类别:
ALLERGY, IMMUNOLOGY & TRANSPLANTATION RESEARCH COMMITTEE
过敏、免疫学
  • 批准号:
    6595161
  • 财政年份:
    1995
  • 资助金额:
    $ 34.88万
  • 项目类别:
ALLERGY, IMMUNOLOGY & TRANSPLANTATION RESEARCH COMMITTEE
过敏、免疫学
  • 批准号:
    6468845
  • 财政年份:
    1995
  • 资助金额:
    $ 34.88万
  • 项目类别:
GENETICS OF HUMAN LYMPHOCYTE ANTIGEN CD8
人类淋巴细胞抗原 CD8 的遗传学
  • 批准号:
    2071071
  • 财政年份:
    1993
  • 资助金额:
    $ 34.88万
  • 项目类别:
GENETICS OF HUMAN LYMPHOCYTE ANTIGEN CD8
人类淋巴细胞抗原 CD8 的遗传学
  • 批准号:
    3149970
  • 财政年份:
    1993
  • 资助金额:
    $ 34.88万
  • 项目类别:
GENETICS OF HUMAN LYMPHOCYTE ANTIGEN CD8
人类淋巴细胞抗原 CD8 的遗传学
  • 批准号:
    2071069
  • 财政年份:
    1993
  • 资助金额:
    $ 34.88万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 34.88万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 34.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了